ReviewFrontiers in neurology2025
External trigeminal nerve stimulation for neuropsychiatric disorders: mechanisms, efficacy, and future directions.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
External trigeminal nerve stimulation (eTNS) is an emerging noninvasive neuromodulation technique that modulates brain network activity implicated in multiple neuropsychiatric disorders through the application of low-intensity electrical currents to the frontal branches of the trigeminal nerve. Based on a search of major biomedical databases, we narratively synthesize clinical and mechanistic studies of eTNS across neurological and psychiatric indications. Current clinical and neurophysiological studies suggest clinically meaningful benefits of eTNS in attention-deficit/hyperactivity disorder (ADHD) and migraine, show promising adjunctive efficacy in epilepsy, and may offer emerging therapeutic potential for conditions such as depression, anxiety, and disorders of consciousness. Although eTNS generally demonstrates a favorable safety profile, existing studies are constrained by small sample sizes, short follow-up periods, and considerable heterogeneity in stimulation parameters, and standardized clinical protocols are still lacking. Future research should prioritize multicenter randomized controlled trials, parameter optimization, and biomarker-guided personalized modulation. By integrating neurophysiological, neuroimaging, and behavioral metrics, such efforts may advance eTNS toward a precisely controlled, closed-loop neuromodulation system. This narrative review provides a concept-driven synthesis of the anatomical foundations, putative mechanisms, and clinical evidence for eTNS and outlines key directions for standardization and translational research, thereby providing a reference framework for the clinical implementation of eTNS in neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.